首页 | 本学科首页   官方微博 | 高级检索  
检索        

厄贝沙坦治疗缺血性心肌病临床评价
引用本文:王海涛,王新民,袁阳.厄贝沙坦治疗缺血性心肌病临床评价[J].医学理论与实践,2002,15(5):504-505.
作者姓名:王海涛  王新民  袁阳
作者单位:解放军107医院急救中心,山东省烟台市,264002
摘    要:目的:评价厄贝沙坦治疗缺血性心肌病心力衰竭的临床疗效。方法:缺血性心肌病病人随机分为治疗组和对照组,其中治疗组22例(厄贝沙坦150mg,qd,PO,加常规处理),对照组20例(常规处理)。详细记录入院时和治疗4周临床症状体征、心脏彩超左室射血分数(LVEF)值及药物不良反应,观察治疗4周心功能恢复情况。结果:治疗组临床心功能改善程度较对照组大(P<0.01),治疗组LVEF改善较对照级更明显(P<0.01),两组均无咳嗽及其他显著不良反应发生。结论:厄贝沙坦能够明显改善缺血性心肌病患者心功能,可明显提高LVEF,不良反应少。

关 键 词:厄贝沙坦  缺血性心肌病  心力衰竭  疗效  LVEF
修稿时间:2002年1月12日

The Assessment of Irbesartan in Treating Ischemic Cardlomyopathy
WANG Haitao,WANG Xinmin,YUAN Yang.The Assessment of Irbesartan in Treating Ischemic Cardlomyopathy[J].The Journal of Medical Theory and Practice,2002,15(5):504-505.
Authors:WANG Haitao  WANG Xinmin  YUAN Yang
Institution:WANG Haitao,WANG Xinmin,YUAN Yang. The 107th Hospital of PLA,Yantai City,Shandong Province 264002
Abstract:Objective:To evaluate the effect of irbesartan in treating ischemic cardiomyopathy.Methods:42 patients with ischemic cardiomyopathy were randomly divided into two groups. 20 patients were admitted to conventional treatment group (control group) ,and the treatment group involved 22 patients who were given irbesartan orally 150mg a day for 4 weeks besides conventionl treatment. Re-Sults:In improving cardiac function and LVEF,treatment group was more obvious than control group (P < 0.01) .There was no obviously adverse reaction found. Conclusion: Irbesartan is a kind of effective medicine which is fit for the treatment of ischemic cardiomyopathy with CHF.
Keywords:Irbesartan  Ischemic cardiomyopathy  Heart failure  Curative effect  LVEF
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号